MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2017 International Congress

    Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study

    N. Titova, N. Sotnikova, E. Katunina (Moscow, Russian Federation)

    Objective: Cross-sectional assessment of personality trait, impulsivity, depression and anxiety collected prospectively in Parkinson’s disease (PD) with impulse control disorders (PD-ICD) compared to a matched…
  • 2017 International Congress

    Exome sequencing in patients with impulse control disorders in Parkinson’s disease: a pilot study

    S. Prud'hon, F. Danjou, S. Bekadar, Y. Marie, A. Rastetter, J. Guégan, F. Cormier-Dequaire, S. Lesage, A. Brice, J.-c. Corvol (Paris, France)

    Objective: To identify genetic variants associated with impulse control disorders (ICD) in Parkinson’s disease (PD) Background: ICD is frequently associated with dopamine agonist (DA) therapy…
  • 2017 International Congress

    Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, B. Berryhill, M. Hacker, D. [email protected], J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…
  • 2017 International Congress

    Dopamine agonist therapy mediates relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease.

    T. Turner, J. Renfroe, V. Hinson (Charleston, SC, USA)

    Objective: Evaluate relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease (PD). Background: Impulse control disorders can be challenging iatrogenic effects of dopamine agonist…
  • 2017 International Congress

    Genetics of impulse control disorders in Parkinson’s disease: a case control study

    J.-C. Corvol, F. Cormier-Dequaire, S. Bekadar, S. Prud'hon, M. Anheim, J.-P. Azulay, F. Durif, J.-L. Houeto, A. Destée, K. Tahiri, G. Mangone, L. Lacomblez, P. Krack, P. Krystkowiak, D. Maltête, O. Rascol, C. Tranchant, M. Vidailhet, A. Brice, S. Tezenas duMontcel (Paris, France)

    Objective: To investigate the association between candidate genes and impulse control disorders (ICD) in patients with Parkinson’s disease. Background: ICD are frequently associated with dopaminergic…
  • 2017 International Congress

    Longitudinal analysis of the relation of dopamine agonist use with impulse control disorders in Parkinson’s disease

    j.-c. corvol, F. Artaud, O. Rascol, F. Durif, P. Derkinderen, F. Bourdain, J.-P. Brandel, f. Pico, L. Lacomblez, C. Bonnet, D. Grabli, S. Klebe, G. Mangone, H. You, v. Mesnage, P.C. Lee, A. Brice, M. Vidailhet, F. Cormier-Dequaire, A. Elbaz (Paris, France)

    Objective: To investigate the longitudinal relationship between dopaminergic therapies and impulse control disorders (ICD) in PD. Background: ICD are frequently associated with dopaminergic therapy, particularly dopamine…
  • 2017 International Congress

    Impulse control disorder and associated clinical factors in drug-naïve Parkinson’s disease.

    D. Gupta, M. Marano, S. Fahn (New York, NY, USA)

    Objective: To investigate various clinical factors associated with Impulse Control Disorders (ICD) in Parkinson's disease (PD) patients who have never been exposed to Dopamine Replacement…
  • 2017 International Congress

    Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment

    R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, R. Chaudhuri, T. Henriksen, T. van Laar, K. Spivey, S. Vel, A. Lees (Vienna, Austria)

    Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…
  • 2017 International Congress

    An association between impulse control disorders and dopamine agonists in Japanese patients with Parkinson’s disease.

    Y. Yamanishi, R. Ando, C. Yamasaki, S. Tada, N. Miyaue, H. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, M. Nomoto (Ehime, Japan)

    Objective: To evaluate an association between impulse control disorders (ICDs) and dopamine agonists (DA) therapy in Japanese patients with Parkinson’s disease (PD). Background: ICDs such…
  • 2017 International Congress

    Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis

    M. Asgharnejad, H. Pesch, E. Dohin (Raleigh, NC, USA)

    Objective: The key aim was to assess the efficacy of rotigotine (RTG) transdermal patch on individual items of Unified Parkinson’s Disease Rating Scale (UPDRS) II…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley